Pasture Holdings has signed a non-binding term sheet with the Government Pharmaceutical Organisation of Thailand to exclusively distribute its Oral Disintegrating Strips (ODS) in the country. This agreement marks a significant step in the commercialisation of Pasture’s proprietary drug delivery system, with a formal distribution agreement anticipated to follow.
The ODS, known as HART-S, contains sildenafil 50mg and offers a discreet, fast-acting alternative to conventional tablets for treating erectile dysfunction. The strips dissolve quickly in the mouth without the need for water, providing enhanced convenience for patients. A clinical trial conducted by Thailand’s Government Pharmaceutical Organisation confirmed the strips’ effectiveness and safety, with a faster onset of action compared to traditional tablets.
Lloyd Soong, Executive Chairman and CEO of Pasture Holdings, highlighted the strategic importance of this agreement, stating, “Our ODS was a cornerstone of our growth story during the IPO. This strategic step with GPO Thailand opens new revenue opportunities and strengthens our regional presence.”
The signing of the term sheet follows extensive negotiations and due diligence, reflecting a shared commitment to advancing innovative healthcare solutions. Pasture Holdings, a Singapore-based global pharmaceutical company, continues to focus on developing accessible drug delivery systems across the region.
As Pasture moves towards a formal distribution agreement, the company aims to expand its presence and offer scalable healthcare solutions that meet evolving market needs.
“`
